Abstract: This disclosure relates to a system and method for custom made medical devices life cycle management, the life cycle management of the medical devices include tracking of material and procedure to be used in additive manufacturing of the medical device and analyzing design risk as per the raw material and the design specification. Further, it includes to identify potential hazards based upon the materials, their interactions and effect on process to be followed. An artificial intelligence (AI) enabled model is trained with one or more sample datasets pertaining to a plurality of materials to be used in the additive manufacturing to audit design, to determine materials to be used, and to generate a unique code to be used to label the manufactured medical device. A smart contract of blockchain is configured to record received input and update with new points for regulatory compliance.

Abstract: This disclosure relates generally to clinical trial management, and more particularly to method of performing a data driven cognitive clinical trial feasibility analysis. In one embodiment, the method comprising (a) receiving, a plurality of protocol requirements to initiate a clinical trial site feasibility; (b) identifying, a plurality of meta-data for at least one protocol requirement from the plurality of protocol requirements; (c) obtaining, an exhaustive list of historic clinical trial site data for the identified meta-data from a site data repository; (d) obtaining, an exhaustive list of third party clinical trial site data for identified meta-data from a third party data repository; and (e) assessing, the exhaustive list of clinical trial site data and the exhaustive list of third party clinical trial site data to obtain a list of identified clinical trial site feasibility.

Abstract: This disclosure relates to a system and method for custom made medical devices life cycle management. the life cycle management of the medical devices include tracking of material and procedure to be used in additive manufacturing of the medical device and analyzing design risk as per the raw material and the design specification. Further, it includes to identify potential hazards based upon the materials, their interactions and effect on process to be followed. An artificial intelligence (AI) enabled model is trained with one or more sample datasets pertaining to a plurality of materials to be used in the additive manufacturing to audit design, to determine materials to be used, and to generate a unique code to be used to label the manufactured medical device. A smart contract of blockchain is configured to record received input and update with new points for regulatory compliance.

Abstract: With the scale of information available today along with the existing diverse channels of communication, manual processing of information is becoming a challenge and companies across industries are under tremendous pressure to lower transactional costs. Artificial Intelligence based automation of business transactions has seen regulatory hurdles due to probabilistic nature of the outcome. The main challenge lies in processing of transactions with unstructured information. Systems and methods of the present disclosure uses deterministic as well as probabilistic approaches to maximize accuracy. The larger use of deterministic approach with configurable components and ontologies helps to improvise accuracy, precision and reduce recall. The probabilistic approach is used when there is absence of quality information or less information for learning. Also, confidence indicators are provided at attribute level of data being processed and at each decision level.

Abstract: This disclosure relates generally to clinical trial management, and more particularly to method of performing a data driven cognitive clinical trial feasibility analysis. In one embodiment, the method comprising (a) receiving, a plurality of protocol requirements to initiate a clinical trial site feasibility; (b) identifying, a plurality of meta-data for at least one protocol requirement from the plurality of protocol requirements; (c) obtaining, an exhaustive list of historic clinical trial site data for the identified meta-data from a site data repository; (d) obtaining, an exhaustive list of third party clinical trial site data for identified meta-data from a third party data repository; and (e) assessing, the exhaustive list of clinical trial site data and the exhaustive list of third party clinical trial site data to obtain a list of identified clinical trial site feasibility.

Abstract: With the scale of information available today along with the existing diverse channels of communication, manual processing of information is becoming a challenge and companies across industries are under tremendous pressure to lower transactional costs. Artificial Intelligence based automation of business transactions has seen regulatory hurdles due to probabilistic nature of the outcome. The main challenge lies in processing of transactions with unstructured information. Systems and methods of the present disclosure uses deterministic as well as probabilistic approaches to maximize accuracy. The larger use of deterministic approach with configurable components and ontologies helps to improvise accuracy, precision and reduce recall. The probabilistic approach is used when there is absence of quality information or less information for learning. Also, confidence indicators are provided at attribute level of data being processed and at each decision level.